Addressing liver fibrosis by TRAIL targetied to hepatic stellate cells

Mohammad Arabpour

Addressing liver fibrosis by TRAIL targetied to hepatic stellate cells

Mohammad Arabpour

Chemische en Farmaceutische Biologie

Onderzoeksoutput

1453 Downloads (Pure)

Samenvatting

De voornaamste complicaties bij patiënten met chronische leverziekte is leverfibrose. Een lever transplantatie is de enige therapeutische optie in het eindstadium van de ziekte. Daarom is een werkbare alternatieve therapie om het fibrotische proces tegen te gaan gewenst. Activering van leverstellaatcellen (Hepatic Stellate Cells, HSC) en afzetting van extracellulaire matrix is het belangrijkste onderliggende mechanisme van leverfibrose. In dit proefschrift werd de toepassing van tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) derivaten en varianten getest als een mogelijke therapie tegen geactiveerde HSCs. Eerdere studies hebben aangetoond dat de verhoging van TRAIL receptoren op het oppervlak van HSCs tijdens de activering geassocieerd is met een toename van de gevoeligheid van de HSCs voor TRAIL-geïnduceerde apoptose (celdood). De korte halfwaardetijd van TRAIL in vivo en de ontwikkeling van anti-apoptotische signalerings mechanismen in TRAIL-resistente geactiveerde HSCs zijn belangrijke hindernissen voor de therapeutische toepassing van TRAIL voor de behandeling van leverfibrose. Dit proefschrift handelt over de toepassing van doelgerichte TRAIL genen en eiwitten als een nieuwe technologie om leverfibrose succesvol te behandelen.

Originele taal-2	English
Kwalificatie	Doctor of Philosophy
Toekennende instantie	Rijksuniversiteit Groningen
Begeleider(s)/adviseur	Haisma, Hidde, Supervisor Poelstra, Klaas, Supervisor
Datum van toekenning	13-mei-2016
Plaats van publicatie	[Groningen]
Uitgever	University of Groningen
Gedrukte ISBN's	978-90-367-8767-3
Elektronische ISBN's	978-90-367-8766-6
Status	Published - 2016

Toegang tot document

Title and contents Final publisher's version, 167 KB
Chapter 1 Final publisher's version, 291 KB
Chapter 2 Final publisher's version, 548 KB
Chapter 3 Final publisher's version, 558 KB
Chapter 4 Final publisher's version, 1,29 MB
Chapter 5 Final publisher's version, 999 KB
Chapter 6 Final publisher's version, 193 KB
Appendices Final publisher's version, 182 KB
Complete thesisFinal publisher's version, 3,1 MB
PropositionsFinal publisher's version, 127 KB

Handle.net

Permanente koppeling

Citeer dit

@phdthesis{e4d3f521adc549a2b7ced5532e248517,

title = "Addressing liver fibrosis by TRAIL targetied to hepatic stellate cells",

abstract = "Liver fibrosis is considered as an end stage liver diseases and the primary cause of need for a liver transplant. The development of liver fibrosis is associated with progressive chronic liver disease. The best anti-fibrotic therapy is the elimination of the underlying disease process. In situations in which treating the underlying etiology is not possible, a specific anti-fibrotic therapy would be highly desirable. To date, many specific anti-fibrotic treatments have been tried, but the lack of overall efficiency and the cytotoxicity associated with these treatments form a barrier for their use in the clinic. The elaboration of the underlying pathophysiology of liver fibrosis showed that, despite the complex nexus of liver injury and the fibrotic process, activated Hepatic Stellate Cells (HSC) play a central role both as a causative and as a effector cell. Therefore, research focusing on the targeted elimination of activated HSCs as the first step in natural resolution of liver fibrosis is warranted. In this research we address this issue by TRAIL targeting to HSCs. Earlier studies have shown that the increase in TRAIL receptors on the surface of HSCs during activation is associated with an increase in HSC susceptibility to the TRAIL apoptosis effect. However, the short half-life of TRAIL in vivo and the development of anti-apoptotic signaling mechanisms that cause TRAIL resistance in activated HSCs have proven to be a major hurdle in enabling the therapeutic application of TRAIL as an option in treating liver fibrosis. This thesis deals with the application of targeting TRAIL genes and proteins as a novel technology having the potential to successfully treat liver fibrosis.",

author = "Mohammad Arabpour",

year = "2016",

language = "English",

isbn = "978-90-367-8767-3",

publisher = "University of Groningen",

school = "University of Groningen",

}

TY - BOOK

T1 - Addressing liver fibrosis by TRAIL targetied to hepatic stellate cells

AU - Arabpour, Mohammad

PY - 2016

Y1 - 2016

N2 - Liver fibrosis is considered as an end stage liver diseases and the primary cause of need for a liver transplant. The development of liver fibrosis is associated with progressive chronic liver disease. The best anti-fibrotic therapy is the elimination of the underlying disease process. In situations in which treating the underlying etiology is not possible, a specific anti-fibrotic therapy would be highly desirable. To date, many specific anti-fibrotic treatments have been tried, but the lack of overall efficiency and the cytotoxicity associated with these treatments form a barrier for their use in the clinic. The elaboration of the underlying pathophysiology of liver fibrosis showed that, despite the complex nexus of liver injury and the fibrotic process, activated Hepatic Stellate Cells (HSC) play a central role both as a causative and as a effector cell. Therefore, research focusing on the targeted elimination of activated HSCs as the first step in natural resolution of liver fibrosis is warranted. In this research we address this issue by TRAIL targeting to HSCs. Earlier studies have shown that the increase in TRAIL receptors on the surface of HSCs during activation is associated with an increase in HSC susceptibility to the TRAIL apoptosis effect. However, the short half-life of TRAIL in vivo and the development of anti-apoptotic signaling mechanisms that cause TRAIL resistance in activated HSCs have proven to be a major hurdle in enabling the therapeutic application of TRAIL as an option in treating liver fibrosis. This thesis deals with the application of targeting TRAIL genes and proteins as a novel technology having the potential to successfully treat liver fibrosis.

AB - Liver fibrosis is considered as an end stage liver diseases and the primary cause of need for a liver transplant. The development of liver fibrosis is associated with progressive chronic liver disease. The best anti-fibrotic therapy is the elimination of the underlying disease process. In situations in which treating the underlying etiology is not possible, a specific anti-fibrotic therapy would be highly desirable. To date, many specific anti-fibrotic treatments have been tried, but the lack of overall efficiency and the cytotoxicity associated with these treatments form a barrier for their use in the clinic. The elaboration of the underlying pathophysiology of liver fibrosis showed that, despite the complex nexus of liver injury and the fibrotic process, activated Hepatic Stellate Cells (HSC) play a central role both as a causative and as a effector cell. Therefore, research focusing on the targeted elimination of activated HSCs as the first step in natural resolution of liver fibrosis is warranted. In this research we address this issue by TRAIL targeting to HSCs. Earlier studies have shown that the increase in TRAIL receptors on the surface of HSCs during activation is associated with an increase in HSC susceptibility to the TRAIL apoptosis effect. However, the short half-life of TRAIL in vivo and the development of anti-apoptotic signaling mechanisms that cause TRAIL resistance in activated HSCs have proven to be a major hurdle in enabling the therapeutic application of TRAIL as an option in treating liver fibrosis. This thesis deals with the application of targeting TRAIL genes and proteins as a novel technology having the potential to successfully treat liver fibrosis.

M3 - Thesis fully internal (DIV)

SN - 978-90-367-8767-3

PB - University of Groningen

CY - [Groningen]

ER -

Addressing liver fibrosis by TRAIL targetied to hepatic stellate cells

Samenvatting

Toegang tot document

Handle.net

Vingerafdruk

Citeer dit